Advancing Earlier Cancer Detection. Accelerating Better Outcomes.
OncoFirm™ is a biotechnology company developing innovative antigen-based diagnostic technologies designed to advance the early detection of cancer. Our proprietary fluorescent lateral flow platform combines rapid testing, sensitive biomarker detection, and digital analysis to support the future of accessible, point-of-care cancer diagnostics.
Innovating the future of early cancer diagnostics — one test at a time.
Why Early Detection Matters
Earlier diagnosis can improve treatment planning and may contribute to better patient outcomes. Expanding access to rapid, high-quality diagnostic technologies has the potential to reduce delays between testing and clinical evaluation.
OncoFirm is committed to developing technologies that support healthcare providers with timely diagnostic information while advancing innovation in oncology diagnostics.
Built for the Future of Point-of-Care Diagnostics
Our vision extends beyond individual diagnostic tests. We are developing an integrated diagnostic ecosystem intended to support healthcare systems, researchers, distributors, and diagnostic partners worldwide.
Antigen Technology
Proprietary antigen technologies engineered for cancer-associated biomarkers.
Lateral Flow Assays
Fluorescent lateral flow assays for enhanced analytical performance.
AI-Assisted Readers
Digital readers designed for AI-assisted interpretation of results.
Cloud-Enabled Data
Cloud-enabled data management built for connected diagnostic workflows.
Multiplex Testing
Future multiplex testing capabilities for broader biomarker panels.
Rapid Point-of-Care Cancer Diagnostics Using Proprietary Fluorescent Lateral Flow Technology
Cancer remains one of the leading causes of death worldwide, and outcomes improve significantly when disease is detected early. Many existing diagnostic methods require centralized laboratories, specialized equipment, extended turnaround times, or invasive procedures.
OncoFirm is developing a platform intended to make cancer biomarker testing faster, more accessible, and easier to deploy across a range of healthcare settings.
Our technology is designed to support:
- Early cancer biomarker detection
- Point-of-care diagnostic testing
- Rapid clinical decision support
- Scalable diagnostic manufacturing
- Digital interpretation through AI-enabled analysis
Proprietary Fluorescent Lateral Flow Technology
At the core of our platform is a proprietary fluorescent lateral flow immunoassay engineered to detect targeted cancer-associated antigens with enhanced analytical performance. By combining advanced immunochemistry with digital diagnostics, OncoFirm is working to expand access to earlier cancer detection technologies.
Our technology platform is being developed to offer:
- High-sensitivity fluorescent detection
- Multiplex biomarker capabilities
- Rapid results
- Portable diagnostic workflows
- Digital result interpretation
- Scalable manufacturing potential
Scientific Innovation with Commercial Potential
OncoFirm is advancing its technology through research, product development, strategic collaborations, and commercialization initiatives. Together, we aim to accelerate the future of accessible cancer diagnostics.
Join Us in Transforming Early Cancer Diagnostics
Whether you are a healthcare provider, researcher, investor, or strategic partner, we invite you to explore how OncoFirm is advancing the next generation of cancer diagnostics through innovative antigen technology.
OncoFirm™ Cancer Biomarker Atlas 2026, First Edition
Explore our latest whitepaper collection covering early cancer detection research, biomarker science, and the evidence base behind point-of-care diagnostic innovation.